Open-Label, Randomized, and Multicenter Phase III Clinical Trial Comparing Immunogenicity of [Hepatitis B vaccine recombinant] Double-Dose (40 microg at S0, S4 and S24), Versus Standard Dose Vaccination (20 microg at S0, S4 and S24), Against Hepatitis B Virus in HIV-1-Infected Patients Without Any Previous Immune Response After Primary Immunization Plus One Single Boost.

Trial Profile

Open-Label, Randomized, and Multicenter Phase III Clinical Trial Comparing Immunogenicity of [Hepatitis B vaccine recombinant] Double-Dose (40 microg at S0, S4 and S24), Versus Standard Dose Vaccination (20 microg at S0, S4 and S24), Against Hepatitis B Virus in HIV-1-Infected Patients Without Any Previous Immune Response After Primary Immunization Plus One Single Boost.

Completed
Phase of Trial: Phase III

Latest Information Update: 03 Feb 2017

At a glance

  • Drugs Hepatitis B vaccine recombinant (Primary)
  • Indications Hepatitis B
  • Focus Pharmacodynamics
  • Acronyms B-BOOST
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 06 Jul 2012 Additional lead trial centre (French National Institute for Health and Medical Research) identified as reported by ClinicalTrials.gov.
    • 18 Jan 2012 Planned end date changed from 1 Nov 2010 to 1 Feb 2013 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top